Two Sigma Advisers’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-583,428
| Closed | -$3.52M | – | 2655 |
|
|
2019
Q4 | $3.52M | Buy |
583,428
+12,000
| +2% | +$69.5K | 0.01% | 980 |
|
|
2019
Q3 | $2.06M | Buy |
571,428
+185,600
| +48% | +$716K | 0.01% | 1098 |
|
|
2019
Q2 | $1.03M | Buy |
385,828
+87,100
| +29% | +$257K | ﹤0.01% | 1498 |
|
|
2019
Q1 | $884K | Sell |
298,728
-9,100
| -3% | -$22.4K | ﹤0.01% | 1584 |
|
|
2018
Q4 | $489K | Buy |
307,828
+293,815
| +2,097% | +$831K | ﹤0.01% | 1786 |
|
|
2018
Q3 | $52K | Sell |
14,013
-20,400
| -59% | -$60.8K | ﹤0.01% | 2174 |
|
|
2018
Q2 | $97K | Buy |
+34,413
| New | +$117K | ﹤0.01% | 2275 |
|
|
2018
Q1 | – | Sell |
-108,913
| Closed | -$314K | – | 2477 |
|
|
2017
Q4 | $314K | Buy |
+108,913
| New | +$396K | ﹤0.01% | 1928 |
|
|
2017
Q1 | – | Sell |
-58,185
| Closed | -$240K | – | 2525 |
|
|
2016
Q4 | $240K | Buy |
58,185
+26,357
| +83% | +$140K | ﹤0.01% | 2124 |
|
|
2016
Q3 | $258K | Buy |
31,828
+8,200
| +35% | +$69.7K | ﹤0.01% | 1941 |
|
|
2016
Q2 | $184K | Sell |
23,628
-13,772
| -37% | -$118K | ﹤0.01% | 1881 |
|
|
2016
Q1 | $289K | Sell |
37,400
-19,600
| -34% | -$144K | ﹤0.01% | 1688 |
|
|
2015
Q4 | $615K | Buy |
+57,000
| New | +$518K | ﹤0.01% | 1255 |
|
|
2014
Q4 | – | Sell |
-94,028
| Closed | -$938K | – | 2903 |
|
|
2014
Q3 | $938K | Buy |
94,028
+21,528
| +30% | +$200K | 0.01% | 1157 |
|
|
2014
Q2 | $549K | Buy |
+72,500
| New | +$289K | ﹤0.01% | 1607 |
|
Two Sigma Advisers's ACHN Position: Q1 2020 in Review
Two Sigma Advisers sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 583,428 shares — an estimated $3.52M sold.
Two Sigma Advisers first reported a position in ACHN in Q2 2014 and held it in 15 quarters. The position peaked at $3.52M in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Two Sigma Advisers reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Two Sigma Advisers sold 583,428 Achillion Pharmaceuticals shares in Q1 2020, an estimated $3.52M.
- Two Sigma Advisers first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 15 quarters.
- Two Sigma Advisers's Achillion Pharmaceuticals position peaked at $3.52M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Two Sigma Advisers's 13F filing for Q1 2020, filed 15 May 2020.